TY - JOUR
AU - Bloomgarden, Zachary
AB - Type 1 diabetes (T1D) is an immune‐mediated illness, with selective destruction of β‐cells occurring in genetically predisposed persons.1 In addition to apoptotic β‐cell destruction after immune damage, a reduction in β‐cell proliferative capacity may play a role in determining which individuals go on to develop T1D. In the present commentary, we discuss several novel approaches that may prove useful in early treatment of T1D. Complex immunomodulatory treatments prior to the onset of clinical disease have been shown to reduce the risk of developing T1D. Such approaches, however, require the identification of very small numbers of predisposed persons in the overall population, a daunting exercise. A German study carried out in more than 150 000 children found only 0.35% to be positive for islet antibodies, of whom only 0.08% progressed to develop diabetes.2 The identification of a number of experimental treatment options for T1D after clinical onset offer intriguing alternative possibilities.Serologic markers such as antibodies to islet cells and glutamic acid decarboxylase‐65 are typically present prior to clinical presentation of disease and lend themselves to measurement, contributing to T1D by presenting islet antigens, including insulin, leading to activation of T cells causing autoimmune destruction of pancreatic beta cells.3 These islet antigens 
TI - Novel approaches to the treatment of type 1 diabetes
JF - Journal of Diabetes
DO - 10.1111/1753-0407.13333
DA - 2022-11-01
UR - https://www.deepdyve.com/lp/wiley/novel-approaches-to-the-treatment-of-type-1-diabetes-4dJEf0e7ui
SP - 724
EP - 726
VL - 14
IS - 11
DP - DeepDyve
ER -